Neoadjuvant Therapy Outcomes Calculator
This software calculates the anticipated 5-year distant metastasis-free survival and disease-specific survival for breast cancer patients following treatment with neoadjuvant chemotherapy. The scoring systems provide a novel means for evaluating prognosis in these patients by incorporating the pretreatment clinical stage and post-treatment pathologic stage (CPS score) as well as estrogen receptor status and tumor grade (CSP+EG score). Please note that this calculator is not applicable for patients presenting with distant metastatic (M1) disease or for patients who go on to develop M1 disease.
Clinical-Pathologic Scoring System | |
Total Score: |
|
5-year Distant Metastasis Free Survival: |
95% CI: |
5-year Disease Specific Survival: | 95% CI: |
Clinical-Pathologic Scoring System incorporating estrogen receptor status and nuclear grade | |
Total Score: | |
5-year Distant Metastasis Free Survival: | 95% CI: |
5-year Disease Specific Survival: | 95% CI: |
Reference: Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008 Jan 10;26(2):246-52.